A phase III randomized clinical trial of Gemcitabine and Nab-Paclitaxel as switch maintenance versus continuation of modified FOLFIRINOX as first-line chemotherapy in patients with advanced pancreatic cancer: The PANThEON Study.
Sciortino C, Nichetti F, Bergamo F, Palermo F, Tamberi S, Vivaldi C, Ongaro E, Arcangeli G, Marchesi S, Giommoni E, Cella CA, Pircher C, Chiaramonte A, Bencardino K, Sottotetti E, Martinetti A, Rapposelli IG, Corallo S, Di Donato S, Murialdo R, Delliponti L, Salvatore L, Bozzarelli S, Dell'Aquila E, Miceli R, Carnaghi C, Tomasello G, Rivizzigno P, Bonomi M, Mannavola F, Forti L, Garajovà I, Attademo L, Galassi B, Chiari R, Leone F, Garattini SK, Tamburini E, Pietrantonio F, Niger M.
Sciortino C, et al. Among authors: tomasello g.
Dig Liver Dis. 2025 Dec;57(12):2470-2477. doi: 10.1016/j.dld.2025.11.007. Epub 2025 Nov 28.
Dig Liver Dis. 2025.
PMID: 41318310
Free article.